Table 1.
Clinical studies on c-Met inhibitors in the treatment of DSTs.
| Conditions | Interventions | First posted | Number enrolled | Phase | NCT number | State | Status |
|---|---|---|---|---|---|---|---|
| Gastric Cancer | Drug: crizotinib | May 6, 2015 | 2 | Phase 2 | NCT02435108 | Korea | Completed |
| Advanced Solid Tumors | Drug:Capmatinib | October 5, 2016 | 36 | Phase 1 | NCT02925104 | United States | Completed |
| Solid Tumors | Drug: Capmatinib | March 29, 2011 | 131 | Phase 1 | NCT01324479 | United States | Completed |
| Gastric Cancer | Drug: MCLA-129 | May 3, 2021 | 150 | Phase 1 Phase 2 |
NCT04868877 | United States | Recruiting |
| Solid Tumors | Genetic: SAIT301 | November 20, 2014 | 16 | Phase 1 | NCT02296879 | Korea | Completed |
| Solid Tumor, Adult | Drug: HLX55 | November 19, 2019 | 98 | Phase 1 | NCT04169178 | Taipei, Taiwan | Recruiting |
| Gastric Cancer Gastroesophageal Junction Adenocarcinoma |
Drug: APL-101 Oral Capsules |
June 5, 2017 | 201 | Phase 1 Phase 2 |
NCT03175224 | United States | Recruiting |
| Solid Tumors | Drug: tepotinib | April 16, 2013 | 12 | Phase 1 | NCT01832506 | Japan | Completed |
| Advanced Solid Tumors Which Are cMET-dependent |
Drug: capmatinib Drug: Nazartinib Drug: Gefitinib |
February 2, 2017 | 40 | Phase 2 | NCT03040973 | United States | Recruiting |
| Solid Tumor | Drug: SPH 3348 | October 21, 2021 | 36 | Phase 1 | NCT05088070 | China | Recruiting |
| Pancreatic Adenocarcinoma Metastatic |
Drug: Cabozantinib Drug: Erlotinib |
July 11, 2017 | 7 | Phase 2 | NCT03213626 | United States | Terminated |
| Colorectal Cancer | Drug: MCLA-129 | June 18, 2021 | 400 | Phase 1 Phase 2 |
NCT04930432 | China | Recruiting |
| Solid Tumors | Drug: tepotinib | November 17, 2009 | 149 | Phase 1 | NCT01014936 | United States | Completed |
| Solid Cancers | Drug: bevacizumab •Drug: MetMAb |
February 17, 2010 | 44 | Phase 1 | NCT01068977 | Completed | |
| Colorectal Cancer | Drug: PF-02341066 Drug: PD-0325901 Drug: Binimetinib |
July 28, 2015 | 82 | Phase 1 | NCT02510001 | United Kingdom | Completed |
| Solid Tumor | Drug: RC108 | November 5, 2020 | 32 | Phase 1 | NCT04617314 | China | Recruiting |
| Solid Tumors | Drug: HS-10241 | May 3, 2016 | 7 | Phase 1 | NCT02759640 | Australia | Completed |
| Solid Tumor | Drug: Tepotinib | December 1, 2020 | 100 | Phase 2 | NCT04647838 | Korea | Recruiting |
| Hepatocellular Carcinoma | Drug: Tepotinib | April 16, 2014 | 66 | Phase 1 Phase 2 |
NCT02115373 | Germany | Completed |
| Liver Cancer | Drug: TIVANTINIB | January 7, 2014 | 386 | Phase 3 | NCT02029157 | Japan | Completed |
| Advanced Solid Tumor | Drug: CAPMATINIB | March 7, 2012 | 44 | Phase 1 | NCT01546428 | Japan | Completed |
| Solid Tumor | Drug: HS-10241 | July 20, 2020 | 30 | Phase 1 | NCT04477057 | China | Recruiting |
| Advanced Solid Tumors | Drug: AMG 337 | December 3, 2010 | 111 | Phase 1 | NCT01253707 | United States | Completed |
| Carcinoma, Hepatocellular | Drug: Foretinib | June 15, 2009 | 45 | Phase 1 | NCT00920192 | Taiwan | Completed |
| Advanced Solid Tumors | Drug: ABT-700 | November 16, 2011 | 74 | Phase 1 | NCT01472016 | Completed |
All clinicaltrials can be downloaded from www.clinicaltrials.gov (accessed February 28, 2022).